Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Gabe Fernandez who wrote (93)	11/6/1998 11:54:00 AM
From: David Israel-Rosen	Read Replies (2) \| Respond to of 1386

Dear Dr: Couldn't have said it myself better. Short Sellers work by creating BAD INFORMATION like PARS is about to be delisted and than regardless of fundamentals sell the stock short. Increaded Short activities which remains unchecked brings about MORE SHORT SELLING. The only way of fighting it is to tell the World that HU211 is is great is We KNOW it is. A release around the LA Conference might do the Trick it will Spike the stock and Will PUNISH the SHORTS which as a result might go SHORT a DIFFERENT STOCK. I PRAY someone at PARs is listening david

To: Gabe Fernandez who wrote (93)	11/6/1998 12:14:00 PM
From: John Goodman	Read Replies (1) \| Respond to of 1386

Gabe, immortal stem cell production has a more far reaching effect on the human condition than PARS and therefore generates greater public attention. Further, if PARS had been above $5 (Geron was $8) when all the good news hit, we may have seen a pump in its share price as well. In the mean time, I'm long PARS and loving it. I can wait for PARS to realize its potential. From the sound of most on this thread, that may not take such a long time to do. John Goodman